AMSBIO Launches a New Range of Genetically Characterized FFPE Tissue Samples

24 Feb 2014
Share
AMSBIO has launched CancerSeq™ - a new range of genetically characterized FFPE tissue samples.

CancerSeq™ samples are prepared from genomic DNA extracted from the FFPE tumor tissues and validated by Next Generation Sequencing using Illumina’s TruSeq Amplicon - Cancer Panel (TSACP).Available as tissue slides and whole blocks, samples are delivered with the mutation and variation data for 48 cancer-related genes including BRAF, KRAS, EGFR, ALK and TP53.

Suitable for a range of applications

CancerSeq™ tissue samples provide researchers with the perfect medium for applications including validation of cancer marker mutation related drug candidates; companion diagnostic assay development ; cellular localization of tissue specific mRNA and protein expression; Comparison of the locations of novel genes in different tissues as well as in situ hybridization, immunohistochemistry, and in situ PCR experiments.


Clinical history data is provided


Available from several tumor tissue types, donor clinical history data is provided with each CancerSeq™ sample. In addition - AMSBIO offers custom services to characterize your specimens or selected samples from its biorepository of cancer and normal FFPE blocks.

Request Info


Company website

AMSBIO
profile photo

Sarah Thomas
Editorial Assistant